References
- Patel U, Kirby R Infections after prostate biopsy and antibiotic resistance. BJU Int. 2008;101:1201–1202.
- Feliciano J, Teper E, Ferrandino M, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy – are fluoroquinolones still effective prophylaxis? J Urol. 2008;179:952–955.
- Uddin MM, Ho HSS, Ng LG, et al. Transrectal prostate biopsy sepsis: trends in its bacteriology and antibiotic prophylaxis in a single center over 8 years. J Urol. 2010;183 Suppl e315:abstract 807.
- Wolf JS Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179:1379–1390.
- Brewster S, MacGowan A, Gingell J. Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam. Br J Urol. 1995;76:351–354.
- Cormio L, Berardi B, Callea A, et al. Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam. BJU Int. 2002;90:700–702.
- Shigemura K, Yasufufu T, Matsumoto M, et al. Can penicillin including beta-lactamase inhibitor overcome febrile complications after transrectal prostate biopsy? J Urol. 2010;183 Suppl e316:abstract 809.
- Clemmens-Funke L, Bittner S, Harringon G. Antibiogram: Regional Medical Laboratory, Battle Creek, MI; 2011.
- Liss MA, Chang A, Santos R, et al, Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol. 2011;185:1283–1288.